Cell division

Bitmis Corp. announces the completion of the reverse merger with Cambell International Holding Limited on December 30, 2022

Retrieved on: 
Friday, December 30, 2022
Research, Cancer, Growth, Immunity, Degenerative disease, Sister republic, News, Diabetes, Vitamin A, Reproduction, Cell division

Panjin City, Liaoning Province, Dec. 30, 2022 (GLOBE NEWSWIRE) -- Bitmis Corp. (OTC Expert Market: BIMT) announced today, December 30, 2022, that it has completed the reverse merger with Cambell International Holding Limited.

Key Points: 
  • Panjin City, Liaoning Province, Dec. 30, 2022 (GLOBE NEWSWIRE) -- Bitmis Corp. (OTC Expert Market: BIMT) announced today, December 30, 2022, that it has completed the reverse merger with Cambell International Holding Limited.
  • Notice Regarding Forward-Looking Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations, or intentions regarding the future.
  • Actual results could differ from those projected in any forward-looking statements due to numerous factors.
  • These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements.

Ensoma Announces $85 Million Financing and Agreement to Acquire Twelve Bio to Advance Portfolio of In Vivo Engineered Cellular Medicines

Retrieved on: 
Thursday, January 5, 2023
Science, Stem Cells, Other Science, Biotechnology, Research, Pharmaceutical, Health, Genetics, Fred Hutchinson Cancer Research Center, Symbiosis, Bill & Melinda Gates Foundation, Protein engineering, Charisma House, Gene editing, Global Investors Summit, Ribosome, Research, Mirae Asset Financial Group, DNA, IT University of Copenhagen, Bill, NNF, Viking Global Investors, Cell division, Series, CRISPR, Cas, Novo Nordisk Foundation, Acquisition, Patient, Qatar Investment Authority, QIA, University, Transcription activator-like effector nuclease, Investment, Hematology, Time-invariant system, Engineering, CRISPR/Cpf1, Cell, Vaccine

Proceeds will enable Ensoma to advance the development of its Engenious™ in vivo engineered cell therapy platform and accelerate its pipeline of genomic medicines for immuno-oncology and other therapeutic applications.

Key Points: 
  • Proceeds will enable Ensoma to advance the development of its Engenious™ in vivo engineered cell therapy platform and accelerate its pipeline of genomic medicines for immuno-oncology and other therapeutic applications.
  • The company also announced it has entered into a definitive agreement to acquire Twelve Bio ApS, a gene editing company pioneering the therapeutic application of next-generation CRISPR-Cas technology.
  • “Ensoma’s platform will enable the next generation of smart immune cell medicines to address complex diseases.
  • “In addition, Ensoma now has the capital, expertise and committed partners necessary to bring our breakthrough medicines to the clinic.

Turbine’s AI-powered Cancer Cell Simulations Will Be Used to Identify Novel Disease Positioning Strategies in Cancer Research UK’s Latest Biotech Partnership

Retrieved on: 
Thursday, January 5, 2023
Technology, Research, Genetics, Biotechnology, Health, Pharmaceutical, Science, Artificial Intelligence, Oncology, Cancer, Bayer, CDC7, Partnership, Drug discovery, Cancer research, DNA, Multimedia, Cancer Research UK, Cell cycle, Cell division, Disease, Patient, Machine learning, Therapy, Simulation, Human, Fine chemical, Pharmaceutical industry, Vaccine, Series, Turbine

Cancer Research Horizons, the innovation engine at the core of the world’s largest private funder of cancer research, Cancer Research UK, is partnering with Turbine,* a tech-enabled biotech leveraging its proprietary Simulated Cell™ platform to solve complex diseases.

Key Points: 
  • Cancer Research Horizons, the innovation engine at the core of the world’s largest private funder of cancer research, Cancer Research UK, is partnering with Turbine,* a tech-enabled biotech leveraging its proprietary Simulated Cell™ platform to solve complex diseases.
  • View the full release here: https://www.businesswire.com/news/home/20230105005158/en/
    The partnership will utilise Turbine’s Simulated Cells™ platform and expertise to identify target patient populations who could benefit from CDC7** inhibitor therapy with Cancer Research Horizons’ lead compound CRT’2199.
  • *** CDC7 is a protein which plays a vital role in the regulation of cell division in normal cells.
  • Turbine will receive a revenue share of Cancer Research Horizon’s future revenues from the CDC7 inhibitor program upon successful commercialisation in exchange for identifying and validating a disease positioning strategy.

MARCH OF DIMES AWARDS PATRICIA HUNT, PHD THE 2022 PRIZE IN DEVELOPMENTAL BIOLOGY FOR RESEARCH ON THE IMPACT OF AGE AND ENVIRONMENTAL EXPOSURES ON PRENATAL DEVELOPMENT AND PREGNANCY

Retrieved on: 
Tuesday, December 20, 2022
March of Dimes Prize in Developmental Biology, Michigan State University, Child, Family, Education, Egg, Case Western Reserve University, Health, Nobel Prize, Faculty, University, Society, Risk, Pregnancy, BPA, Emory University, Nobel Prize in Physiology or Medicine, Cell division, Developmental biology, Developmental Biology (journal), Mouse, Regent, Multimedia, Jackson, Plastic, University of Hawaiʻi, Meiosis, Mother, Reproductive biology, Ageing, Pediatrics, Science, Doctor of Philosophy, Washington State University, MS, Research, BS, University of Colorado Denver School of Public Affairs, Medicine, Dime, Genetics, Physiology

This annual award honors an outstanding scientist who has advanced the science that underlies our understanding of pregnancy, birth and prenatal development.

Key Points: 
  • This annual award honors an outstanding scientist who has advanced the science that underlies our understanding of pregnancy, birth and prenatal development.
  • It carries a $150,000 award and is part of March of Dimes' research strategy to address the multi-faceted nature of the maternal and child health crisis.
  • To date, six recipients have gone on to win the Nobel Prize in Physiology or Medicine.
  • Throughout her career, Dr. Hunt has focused on understanding how prenatal development is impacted by aging, mistakes in meiosis, and environmental contaminants.

Researchers from Insilico Medicine, University of Copenhagen, and University of Chicago unravel molecular secrets hidden in premature aging diseases and cancer using AI

Retrieved on: 
Thursday, December 1, 2022
COVID-19, Doctor of Philosophy, University of Copenhagen, Peripheral nervous system, DNA repair, AI, University, Chemistry, DNA, Gene, Degenerative disease, Associate, Patient, Survival analysis, Ageing, Biomarker, Insilico Medicine, Disease, MD, PLK1, Human, Assistant, Cancer, Cell division, ALS, Hope, Chicago (franchise), Research, Immunity, Gene expression, Intelligence, Fibrosis, Publication, Nature Cell Biology, Medicine, Sarcoma, Survival, Amyotrophic lateral sclerosis, University of Copenhagen Faculty of Health and Medical Sciences, Biology, Longevity, Safety, Idiopathic pulmonary fibrosis, Algorithm, Medical device, Pharmaceutical industry, Vaccine, CEP135

The findings, supported by researchers from the University of Chicago, were published in the Nov. 26 edition of Nature Cell Death & Disease .

Key Points: 
  • The findings, supported by researchers from the University of Chicago, were published in the Nov. 26 edition of Nature Cell Death & Disease .
  • With the most significantly perturbed genes serving as biomarkers, researchers performed survival analysis across 33 cancer types and selected those that showed high confidence stratification among cancer patients.
  • Insilico Medicines AI-driven PandaOmics platform was used to perform a comprehensive differential gene expression analysis, survival stratification, and target discovery.
  • Insilico Medicine is delivering breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, and aging-related diseases.

Ovation Fertility Licenses Genomic Prediction's LifeView PGT to Provide Patients with the Most Advanced Testing Available

Retrieved on: 
Thursday, October 20, 2022
Method, Genetic counseling, CSO, Risk, Laboratory, Family, Parent, Adult, Patient, Aneuploidy, Genetic testing, Mosaic, Comparison, Cancer, Ovation, NGS, Egg, IVF, Fertility, Physician, Gene, Genetics, Clinical trial, Infertility, Cell division, PGT, Pregnancy, Scores, Birth control, Pharmaceutical industry, Medical device

"This collaboration will provide Ovation patients with access to state-of-the-art technology and improved clinical care," said Paul Kappelman, chief executive officer of Ovation Fertility.

Key Points: 
  • "This collaboration will provide Ovation patients with access to state-of-the-art technology and improved clinical care," said Paul Kappelman, chief executive officer of Ovation Fertility.
  • With LifeView PGT for structural rearrangements (PGT-SR), patients have the option to select an embryo that does not carry the same balanced translocation that they do.
  • Physicians partner with Ovation to offer their patients advanced preconception carrier screening; preimplantation genetic testing; donor egg and surrogacy services; and secure storage for their frozen eggs, embryos and sperm.
  • Learn more about Genomic Prediction's LifeView PGT testing at: www.lifeview.com
    Wiemer et al.

Discovery of 119-million-year-old selfish genes in yeast potentially alters our understanding of how parasitic DNA impacts genome evolution

Retrieved on: 
Wednesday, October 19, 2022
National Institute, American Century Companies, Stowers Institute for Medical Research, Biology, Doctor of Philosophy, Thought, Technology, Life, Population, Medical research, Association, Longevity, Perception, NIH, Institute, Multimedia, New, Mutation, Health, National, Spore, Egg, Meiosis, National Institutes of Health Office of Science Policy, Infertility, Genome, Fertility, Cell division, Chromosome, Gene, Human, Agriculture, Pharmaceutical industry, Antibiotics, Science, ELife

Meiotic drivers are thus named as they can acquire the ability to literally "drive" the transmission of their genes throughout a genome, often with negative consequences.

Key Points: 
  • Meiotic drivers are thus named as they can acquire the ability to literally "drive" the transmission of their genes throughout a genome, often with negative consequences.
  • Natural selection in a genome typically rescues a species from selfish genes by favoring genes that suppress, or silence drive, rendering it useless.
  • It also changes the way scientists may look for and identify families of selfish genes in different species, including humans.
  • "Since selfish genes are major drivers of evolution, this new finding opens the door for thinking about how drivers can have persistent, long-term effects on genome evolution."

EQS-News: DEFENCE THERAPEUTICS INITIATES LUNG CANCER TREATMENT PROGRAM WITH ITS NOVEL ACCUTOXTM FORMULATION VIA INTRANASAL

Retrieved on: 
Wednesday, October 12, 2022
Therapy, Hand, DNA repair, Vaccine, CAGR, Neoplasm, DNA replication, Research, Malignancy, Cell, Technology, Cancer, Infection, Chemistry (relationship), Lung cancer, Company, Cell death, CSE, CEO, ADC, Small-cell carcinoma, News, Genome, Defense, Forward-looking statement, DNA, Cell division, Catastrophic illness, USD, Carcinoid syndrome, Engineering, Control, Large-cell lung carcinoma, Security (finance), BC

The novel AccuTOXTM formulation is designed for the treatment of lung cancer including various types of malignancy of the upper or lower respiratory tracks.

Key Points: 
  • The novel AccuTOXTM formulation is designed for the treatment of lung cancer including various types of malignancy of the upper or lower respiratory tracks.
  • The AccuTOXTM will be delivered intranasal to effectively deliver the AccuTOXTM into the transmucosal and will target the lungs.
  • The AccuTOXTM technology is an AccumTM variant developed by Defence Therapeutics to specifically halt tumor growth when administered intratumorally.
  • Small cell lung cancer, lung carcinoid tumor and non-small cell lung cancer are three different types of lung cancer.

Hydroponic System Market worth $25.1 billion by 2027 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Friday, September 23, 2022
Knowledge, Humidity, Enlargement, GEM, Adoption, Light, Health, Fertilisation, Temperature, Groundwater, NPK, Ageing, NFT, Maximal and minimal elements, Growth, Review, Gibberellin, Hydroponics, MH, Component, USD, Fruit, Region, Aeroponics, HPS, Cell division, Breeding, Nutrient, Urban, Intelligence, Technology, Wind, SME, LED, Cell, Flower, Chloroplast, EC, Research, Building, Greenhouse, Cytokinin, Vegetable, CAGR, Fertilizer, Agriculture, Marketing, Aquaponics

CHICAGO, Sept. 23, 2022 /PRNewswire/ --The Hydroponics Market is valued at USD 12.1 billion in 2022 and is projected to reach USD 25.1 billion by 2027.

Key Points: 
  • CHICAGO, Sept. 23, 2022 /PRNewswire/ --The Hydroponics Market is valued at USD 12.1 billion in 2022 and is projected to reach USD 25.1 billion by 2027.
  • The global hydroponics crop market is estimated to be valued at USD 37.7 billion in 2022 and is projected to reach USD 53.4 billion by 2027, recording a CAGR of 7.2% from 2022 to 2027, according to a new report by MarketsandMarkets.
  • Based on types, the liquid systems segment gained the largest market share in the hydroponics market.
  • Based on equipment, the LED grow light segment accounted for the largest market share in the hydroponics market.

Hydroponic System Market worth $25.1 billion by 2027 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Friday, September 23, 2022
Knowledge, Humidity, Enlargement, GEM, Adoption, Light, Health, Fertilisation, Temperature, Groundwater, NPK, Ageing, NFT, Maximal and minimal elements, Growth, Review, Gibberellin, Hydroponics, MH, Component, USD, Fruit, Region, Aeroponics, HPS, Cell division, Breeding, Nutrient, Urban, Intelligence, Technology, Wind, SME, LED, Cell, Flower, Chloroplast, EC, Research, Building, Greenhouse, Cytokinin, Vegetable, CAGR, Fertilizer, Agriculture, Marketing, Aquaponics

CHICAGO, Sept. 23, 2022 /PRNewswire/ --The Hydroponics Market is valued at USD 12.1 billion in 2022 and is projected to reach USD 25.1 billion by 2027.

Key Points: 
  • CHICAGO, Sept. 23, 2022 /PRNewswire/ --The Hydroponics Market is valued at USD 12.1 billion in 2022 and is projected to reach USD 25.1 billion by 2027.
  • The global hydroponics crop market is estimated to be valued at USD 37.7 billion in 2022 and is projected to reach USD 53.4 billion by 2027, recording a CAGR of 7.2% from 2022 to 2027, according to a new report by MarketsandMarkets.
  • Based on types, the liquid systems segment gained the largest market share in the hydroponics market.
  • Based on equipment, the LED grow light segment accounted for the largest market share in the hydroponics market.